Alfasigma's $800 million buyout of Intercept Pharma two years ago is starting to look like a poor bet, as its only approved product, Ocaliva, is pulled off the market in the US and all trials of the ...

Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty liver disease known as NASH following a rejection. Intercept’s CEO ...

Background The National Heart Failure Audit gathers data on patients coded at discharge (or death) as having heart failure as ...

Objectives to describe the evolution of anxiety during the COVID-19 pandemic in France and to assess whether it differed according to pre-existing alcohol misuse. Design A prospective longitudinal ...

Objective Anxiety affects up to one-third of adults with asthma and is linked to poorer disease outcomes and reduced quality ...